{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:34:07Z","timestamp":1791387247336,"version":"4.3.3"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.msard.2025.106869","type":"journal-article","created":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T22:51:21Z","timestamp":1763938281000},"page":"106869","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Sex differences in multiple sclerosis treatment with disease modifying drugs: a step towards gender neurology"],"prefix":"10.1016","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0635-4756","authenticated-orcid":false,"given":"Ludovico","family":"Baiamonte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Enea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vaccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2516-1567","authenticated-orcid":false,"given":"Paolo","family":"Ragonese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Salemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106869_bib0001","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.3390\/ijms24076354","article-title":"Sex and gender differences in neurodegenerative diseases: challenges for therapeutic opportunities","volume":"24","author":"Bianco","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2025.106869_bib0002","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40263-022-00965-7","article-title":"High-efficacy therapies for treatment-na\u00efve individuals with relapsing-remitting multiple sclerosis","volume":"36","author":"Freeman","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2025.106869_bib0003","doi-asserted-by":"crossref","DOI":"10.1111\/ene.15439","article-title":"Mapping of European activities on the integration of sex and gender factors in neurology and neuroscience","author":"Hentzen","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106869_bib0004","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.yfrne.2018.07.001","article-title":"A case for gender-based approach to multiple sclerosis therapeutics","volume":"50","author":"Houtchens","year":"2018","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.msard.2025.106869_bib0005","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00415-009-0093-1","article-title":"The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL","volume":"256","author":"Hutchinson","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106869_bib0006","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.msard.2025.106869_bib0007","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.msard.2017.01.001","article-title":"Sex differences in outcomes of disease-modifying treatments for multiple sclerosis: a systematic review","volume":"12","author":"Li","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106869_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106348","article-title":"Women and multiple sclerosis: from gender medicine to precision medicine","volume":"96","author":"Lorefice","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106869_bib0009","first-page":"B5212","article-title":"Gender differences in multiple sclerosis epidemiology and treatment response","volume":"63","author":"Magyari","year":"2016","journal-title":"Dan. Med. J."},{"key":"10.1016\/j.msard.2025.106869_bib0010","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/ane.12277","article-title":"Gender effects on treatment response to interferon-beta in multiple sclerosis","volume":"130","author":"Magyari","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2025.106869_bib0011","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.804","article-title":"Gender differences in safety issues during Fingolimod therapy: evidence from a real-life relapsing Multiple Sclerosis cohort","volume":"7","author":"Manni","year":"2017","journal-title":"Brain Behav"},{"key":"10.1016\/j.msard.2025.106869_bib0012","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2025.106869_bib0013","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/M14-0698","article-title":"Transparent reporting of a multivariable prediction model for Individual prognosis or diagnosis (TRIPOD): explanation and elaboration","volume":"162","author":"Moons","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.msard.2025.106869_bib0014","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jclinepi.2016.02.031","article-title":"Adequate sample size for developing prediction models is not simply related to events per variable","volume":"76","author":"Ogundimu","year":"2016","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.msard.2025.106869_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074111","article-title":"Subcutaneous interferon \u03b2-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study","volume":"8","author":"Patti","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.msard.2025.106869_bib0016","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/1352458510384605","article-title":"Gender effects on intramuscular interferon beta-1a in relapsing\u2013remitting multiple sclerosis: analysis of 1406 patients","volume":"17","author":"Rudick","year":"2011","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106869_bib0017","series-title":"The Fundamentals of People Analytics: With Applications in R","first-page":"181","article-title":"Linear regression","author":"Starbuck","year":"2023"},{"key":"10.1016\/j.msard.2025.106869_bib0018","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12874-020-0906-6","article-title":"Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis","volume":"20","author":"St\u00fchler","year":"2020","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.msard.2025.106869_bib0019","first-page":"155","article-title":"The Italian multiple sclerosis register","volume":"40","author":"Trojano","year":"2019","journal-title":"Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol."},{"key":"10.1016\/j.msard.2025.106869_bib0020","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jns.2009.06.036","article-title":"Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment","volume":"286","author":"Trojano","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106869_bib0021","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.msard.2015.06.005","article-title":"GLACIER: an open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis","volume":"4","author":"Wolinsky","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106869_bib0022","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ana.21079","article-title":"Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial","volume":"61","author":"Wolinsky","year":"2007","journal-title":"Ann. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500611X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500611X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:29:16Z","timestamp":1781076556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482500611X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":22,"alternative-id":["S221103482500611X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106869","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sex differences in multiple sclerosis treatment with disease modifying drugs: a step towards gender neurology","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106869","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106869"}}